Please login to the form below

Not currently logged in

Lilly links up with Precision BioSciences in genome editing deal

Eli Lilly new HQPrecision will receive an upfront cash payment of $100m

UPDATED: BMS completes $13.1bn acquisition of MyoKardia

BMS buildingAcquisition will bolster pipeline with targeted cardiovascular therapies

EU secures 405 million doses of CureVac’s COVID-19 vaccine

EU flag bodyCureVac revealed early stage data for its vaccine earlier this month

UCB boosts gene therapy offering with a pair of new deals

UCBCompany will collaborate with Lacerta Therapeutics and acquire Handl Therapeutics

EU agrees on supply deal for 200 million doses of Pfizer, BioNTech's COVID-19 vaccine

EU flagEuropean Commission will have an option to request another 100 million doses

Pfizer, BioNTech set to price COVID-19 vaccine ‘well below typical market rates’

Pfizer BiontechChief strategy officer revealed plans at FT virtual event

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Danish pharma will acquire all outstanding shares in Emisphere

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

Merck & Co HQThe deal will give Merck control of VLS-101, an antibody-drug conjugate

Business in the USAHealth coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

  • Ho_Ung_KimStanding out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

  • HeadsThe diseased organisation

    Like humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...